Suppressive subtractive hybridisation reveals differential expression of serglycin, sorcin, bone marrow proteoglycan and prostate-tumour-inducing gene I (PTI-1) in drug-resistant and sensitive tumour cell lines of haematopoetic origin

European Journal of Cancer

Volumn 35, Issue 12, 1999, Pages 1735-1742

  Beyer Sehlmeyer, G ^a   Hiddemann, W ^b   Wormann B ^a   Bertram, J ^a  

^a R Koch Str 40 D 37075 ^*  (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bone marrow proteoglycan; Drug resistance; Haematopoetic cell lines; Proto oncogene PTI 1; Serglycin; Sorcin; Subtractive suppressive hybridisation

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; PROTEOGLYCAN; SERGLYCIN; SORCIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR INDUCING GENE 1; PROTO ONCOGENE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; CALCIUM-BINDING PROTEINS; CISPLATIN; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; METHOTREXATE; NEOPLASMS; ONCOGENE PROTEINS; PEPTIDE ELONGATION FACTOR 1; PROTEOGLYCANS; TUMOR CELLS, CULTURED; TUMOR STEM CELLS; VESICULAR TRANSPORT PROTEINS; VINCRISTINE;

EID: 0033400037     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00202-6     Document Type: Article

References (37)

1. Kinsella A.R., Smith D., Pickard M. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br. J. Cancer. 75:1997;935-945.
2. Fisher D.E. Apoptosis in cancer therapy: crossing the threshold. Cell. 78:1994;539-542.
3. Holle L.M. Pegasparagase: an alternative? Ann. Pharmacother. 31:1997;616-624.
4. Jordan A., Hadfield J.A., Lawrence N.J., McGown A.T. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med. Res. Rev. 18:1998;259-296.
5. Rustum Y.M., Harstrick A., Cao S.et al. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol. 15:1997;389-400.
6. Pindur U., Lernster T. Antiturnour drug design: DNA-binding ligands, which inhibit the topoisomeraseI. Pharmazie. 53:1998;79-86.
7. Gottlicher M., Heck S., Herflich P. Transcriptional cross-talk, the second mode of steroid hormone receptor action. J. Mol. Med. 76:1998;489-489.
8. Nooter K., Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol. Res. Pract. 192:1996;768-780.
9. McGuire J.J., Magee K.J., Russell C.A., Canestrari J.M. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines. Oncol. Res. 9:1997;139-147.
10. Liu N., Lamerdin J.E., Tebbs R.S.et al. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damage. Mol. Cell. 1:1998;783-793.
11. Colvin O.M. Drug resistance in the treatment of sarcomas. Semin. Oncol. 24:1997;580-591.
12. List A.F. Non-P-glycoprotein drug export mechanisms of multidrug resistance. Semin. Hematol. 34:1997;20-24.
13. Hannun Y.A. Apoptosis and the dilemma of cancer chemotherapy. Blood. 89:1997;1845-1853.
14. Rowan S., Fisher D.E. Mechanisms of apoptotic cell death. Leukemia. 11:1997;457-465.
15. Landowski T.H., Gleason-Guzinan M.C., Dallon W.S. Selection for drug resistance results in resistance to FAS-mediated apoptosis. Blood. 89:1997;1854-1861.
16. Dassonneville L., Bailly C. Chromosome translocations and leukemias induced by inhibitors of topoisomerase II anticarcinogenesis drugs. Bull. Cancer. 85:1998;254-261.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Meth. 65:1983;55-61.
18. Chirgwin J.M., Przybyla A.E., MacDonald R.J., Rutter W.J. Isolation of biologically active ribonucleic acid from sources enriched in ribonulease. Biochemistry. 18:1979;5294-5299.
19. R. Eur. J. Cancer. 34:1998;731-736.
20. Chornczysnki P. One-hour downward alkaline capillary transfer for blotting of DNA and RNA. Analyt. Biochem. 201:1992;134-139.
21. Sharp S.Y., Smith V., Hobbs S., Kelland L.R. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines. Br. J. Cancer. 78:1998;175-180.
22. Zaniboni A., Labianca R., Martignoni G.et al. Sequential methotrexate and 5-fluorouracil as second-line chemotherapy for advanced colorectal cancer patients pretreated with 5-fluorouracil and leucovorin: a GISCAD study. J. Chemother. 8:1998;82-84.
23. Csermely P., Schnaider T., Soti C., Prohaska Z., Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol. Ther. 79:1998;129-168.
24. Shen R., Su Z.Z., Olsson C.A., Fisher P.B. Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. Proc. Natl. Acad. Sci. USA. 92:1995;6778-6782.
25. Paciucci R., Berrozpe G., Tora M., Navarro E., Garcia-de-Herreros A., Real F.X. Isolation of tissue-type plasminogen activator, cathepsin H, and non-specific cross-reacting antigen from SK-PC-1 pancreas cancer using subtractive hybridization. FEBS Lett. 385:1996;72-76.
26. Bao L., Loda M., Janmey P.A., Stewart R., Anand-Apte B., Zetter B.R. Thymosin β15: a novel regulator of tumour cell motility upregulated in metastatic prostate cancer. Nat. Med. 1:1996;1322-1328.
27. Robinson L., Panayiotakis A., Papas T.S., Kola I., Seth A. ETS target genes: identification of egr1 as a target by RNA differential display and whole genome PCR techniques. Proc. Natl. Acad. Sci. USA. 94:1997;7170-7175.
28. Meyers M.B., Zamparelli C., Verzili C., Dicker A.P., Blanck T.J.J., Chiancone E. Calcium-dependent translocation of sorcin to membranes: functional relevance in contractile tissue. FEBS Lett. 357:1995;230-234.
29. Popken-Harris P., Checkel J., Loegering D.et al. Regulation and processing of a precursor form of eosinophil granule major basic protein (ProMBP) in differentiating eosinophils. Blood. 92:1998;623-631.
30. Wang S.L., Tam M.F., Ho Y.S., Pai S.H., Kao M.C. Isolation and molecular cloning of human sorcin: a calcium-binding protein in vincristine-resistant HOB1 lymphoma cells. Biochim. Biophys. Acta. 1260:1995;285-293.
31. Gold J.S., Bao L., Ghoussoub R.A., Zetter B.R., Rimin D.L. Localization and quantitation of expression of the cell motility-related protein thymosin beta15 in human breast tissue. Mod. Pathol. 10:1997;1106-1112.
32. 2+ accompany basophil activation by eosinophil granule major basic protein. Immunol. Lett. 58:1997;37-42.
33. Rabbani S.A., Xing R.H. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int. J. Oncol. 12:1998;911-920.
34. Braun D.P., Preissler H.D. Cytolytic activity of peripheral blood blast cells from patients with acute myeloid leukemia. Leukemia Lymphoma. 27:1997;459-467.
35. Kayagaki N., Kawasaki A., Ebata T.et al. Metalloproteinase-mediated release of human FAS ligand. J. Exp. Med. 182:1995;1777-1783.
36. Schneider P., Holler N., Bodmer J.L.et al. Conversion of membrane-bound FAS (CD 95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1998;1205-1213.
37. Tanaka M., Itai T., Adachi M., Nagata S. Downregulation of FAS ligand by shedding. Nat. Med. 4:1998;31-36.